| Literature DB >> 21410942 |
Jing Qin Wu1, Dominic E Dwyer, Wayne B Dyer, Yee Hwa Yang, Bin Wang, Nitin K Saksena.
Abstract
BACKGROUND: HIV preferentially infects CD4+ T cells, and the functional impairment and numerical decline of CD4+ and CD8+ T cells characterize HIV disease. The numerical decline of CD4+ and CD8+ T cells affects the optimal ratio between the two cell types necessary for immune regulation. Therefore, this work aimed to define the genomic basis of HIV interactions with the cellular transcriptome of both CD4+ and CD8+ T cells.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21410942 PMCID: PMC3068086 DOI: 10.1186/1742-4690-8-18
Source DB: PubMed Journal: Retrovirology ISSN: 1742-4690 Impact factor: 4.602
Patient clinical detail
| Patient | Group | Age | Viral load (copies/ml) | CD4 counts (cells/μl) | CD8 counts (cells/μl) |
|---|---|---|---|---|---|
| V1 | VIR | 46 | 209 | 300 | 566 |
| V2 | VIR | 41 | 2530 | 278 | 845 |
| V3 | VIR | 40 | 5710 | 324 | 1169 |
| V4 | VIR | 43 | 546,000 | 94 | 312 |
| V5 | VIR | 60 | 683,000 | 48 | 73 |
| B1 | BDL | 48 | < 50 | 450 | 288 |
| B2 | BDL | 63 | < 50 | 480 | 360 |
| B3 | BDL | 40 | < 50 | 1065 | 1065 |
| B4 | BDL | 62 | < 50 | 776 | 1692 |
| B5 | BDL | 59 | < 50 | 251 | 548 |
| L1 | LTNP | 59 | < 50 | 630 | 579 |
| L2 | LTNP | 51 | < 50 | 714 | 476 |
| L3 | LTNP | 79 | < 50 | 920 | 900 |
| L4 | LTNP | 33 | 57 | 780 | 900 |
V1-5: viremic patients on HAART; B1-5: aviremic patients on HAART; L1-4: long-term non-progressors. All the patients and seronegative controls are males.
Plasma viral load was measured using the Quantiplex HIV RNA3.0 (Chiron bDNA) assay with a lower limit of detection of 50 HIV-1 copies/ml (Chiron Diagnostics, Halstead, United Kingdom).
Number of differentially expressed genes in pairwise comparisons for CD4+ and CD8+ T cells (fold change > 2 and B-statistic > 0)
| Differentially expressed genes | CD4 | CD8 | CD4 and CD8 | |||
|---|---|---|---|---|---|---|
| up | down | up | down | up | down | |
| BDLvsNEG | 50 | 24 | 206 | 72 | 15 | 3 |
| VIRvsNEG | 173 | 128 | 477 | 273 | 79 | 48 |
| LTNPvsNEG | 5 | 9 | 17 | 6 | 0 | 0 |
| BDLvsLTNP | 0 | 3 | 3 | 1 | 0 | 0 |
| VIRvsLTNP | 29 | 7 | 118 | 63 | 10 | 2 |
| BDLvsVIR | 1 | 8 | 5 | 12 | 0 | 1 |
Up: up-regulation; down: down-regulation; vs: versus; CD4 and CD8: genes differentially expressed in both CD4+ and CD8+ T cells in the same paired comparison.
Figure 1Gene ontology (GO) tree and bar chart for the enriched GO categories. GO categories with at least 2 genes and p < 0.01 are identified as enriched and colored red in the GOTree. In GOTree, O stands for observed gene number in the category; E for expected gene number in the category; R for ratio of enrichment for the category; and P for p value calculated from the statistical test given for the categories with R > 1 to indicate the significance of enrichment. A. GO tree for the differentially expressed genes in CD4+ T cells between the BDL and VIR groups. B. GO tree for the differentially expressed genes in CD4+ T cells between the VIR and LTNP groups. C. GO tree for the differentially expressed genes in CD8+ T cells between the VIR and LTNP groups. D. Bar chart of level 7 categories under cellular component category for CD8+ T cells between the VIR and LTNP groups.
qPCR validation of differentially expressed genes
| Gene | Description | Fwd Primer | Fwd Primer Seq | Rev Primer | Rev Primer Seq | Paired | Cell | FC | FC | |
|---|---|---|---|---|---|---|---|---|---|---|
| KLRD1 | NM_002262.2 | killer cell lectin-like receptor subfamily D, member 1 | KLRD1L | gtgggagaatggctctgc | KLRD1R | tttgtattaaaagtttcaaatgatgga | BDLvsLTNP | CD8 | 2.5 | 2.1 |
| IRS2 | NM_003749.2 | insulin receptor substrate 2 | IRS2L | tgacttcttgtcccaccactt | IRS2R | catcctggtgataaagccaga | BDLvsVIR | CD8 | 3.8 | 2.7 |
| GBP1 | NM_002053.2 | guanylate binding protein 1, interferon-inducible | GBP1L | aggccacatcctagttctgc | GBP1R | tccaggagtcattctggttgt | BDLvsVIR | CD8 | -2.5 | -2.4 |
| ACTA2 | NM_001613.1 | actin, alpha 2, smooth muscle, aorta | ACTA2L | ctgttccagccatccttcat | ACTA2R | tcatgatgctgttgtaggtggt | BDLvsVIR | CD8 | -1.3 | -2.2 |
| ATP6V1D | NM_015994.2 | ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D | ATP6V1DL | ttttcactagctgaagccaagtt | ATP6V1DR | gcgctttattgacattttggat | VIRvsLTNP | CD8 | 2.0 | 2.8 |
| BAG3 | NM_004281.3 | BCL2-associated athanogene 3 | BAG3L | cagccagataaacagtgtggac | BAG3R | agaggcagctggagactgg | VIRvsLTNP | CD8 | -1.5 | -2.4 |
| ACTA2 | NM_001613.1 | actin, alpha 2, smooth muscle, aorta | ACTA2L | ctgttccagccatccttcat | ACTA2R | tcatgatgctgttgtaggtggt | VIRvsLTNP | CD8 | 4.3 | 2.8 |
| PSMB2 | NM_002794.3 | proteasome subunit, beta type, 2 | PSMB2L | agagggcagtggaactcctt | PSMB2R | gaaggttggcagattcagga | VIRvsLTNP | CD8 | 1.3 | 2.3 |
| PSMA5 | NM_002790.2 | proteasome subunit, alpha type, 5 | PSMA5L | tgaatgcaacaaacattgagc | PSMA5R | ttcttcctttgtgaacatgtgg | VIRvsLTNP | CD8 | 2.7 | 2.7 |
| C1QB | NM_000491.3 | complement component 1, q subcomponent, B chain | C1QBL | ggcctcacaggacaccag | C1QBR | ccatgggatcttcatcatcata | BDLvsVIR | CD4 | -4.8 | -4.8 |
| C1QC | NM_172369.3 | complement component 1, q subcomponent, C chain | C1QCL | aaggatgggtacgacggact | C1QCR | ttctgccctttgggtcct | BDLvsVIR | CD4 | -5.6 | -4.1 |
| SERPING1 | NM_000062.2 | serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, | SERPING1L | ctccttacccaggtcctgct | SERPING1R | ggatgctctccaggtttgtt | BDLvsVIR | CD4 | -5.0 | -2.6 |
| C1QB | NM_000491.3 | complement component 1, q subcomponent, B chain | C1QBL | ggcctcacaggacaccag | C1QBR | ccatgggatcttcatcatcata | VIRvsLTNP | CD4 | 6.1 | 6.0 |
| C1QC | NM_172369.3 | complement component 1, q subcomponent, C chain | C1QCL | aaggatgggtacgacggact | C1QCR | ttctgccctttgggtcct | VIRvsLTNP | CD4 | 7.3 | 4.4 |
| SERPING1 | NM_000062.2 | serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, | SERPING1L | ctccttacccaggtcctgct | SERPING1R | ggatgctctccaggtttgtt | VIRvsLTNP | CD4 | 5.3 | 2.8 |
FC_qPCR: fold change by qPCR; FC_MA: fold change by microarray
Number of enriched gene sets in pairwise comparisons for CD4+ and CD8+ T cells using gene set enrichment analysis (at level of FDR < 0.05 and FDR < 0.1)
| FDR < 0.05 | CD4 | CD8 | CD4 and CD8 | |||
|---|---|---|---|---|---|---|
| Enriched gene sets | up | down | up | down | up | down |
| VIRvsBDL | 19 | 3 | 29 | 2 | 5 | 2 |
| VIRvsLTNP | 27 | 2 | 8 | 0 | 6 | 0 |
| BDLvsLTNP | 20 | 7 | 0 | 1 | 0 | 1 |
| Enriched gene sets | up | down | up | down | up | down |
| VIRvsBDL | 57 | 3 | 53 | 2 | 18 | 2 |
| VIRvsLTNP | 51 | 4 | 20 | 0 | 13 | 0 |
| BDLvsLTNP | 31 | 34 | 0 | 5 | 0 | 3 |
Up: up-regulation; down: down-regulation; vs: versus; CD4 and CD8: gene sets enriched in both CD4+ and CD8+ T cells in the same paired comparison.
Figure 2Gene set number plots against the FDR value from GSEA and the corresponding volcano plots visualizing the number of differentially expressed genes. Each differentially expressed gene is represented by a blue dot. A. Volcano plot for CD4+ T cells between BDL and LTNP groups. B. Volcano plot for CD8+ T cells between BDL and LTNP groups. C. Volcano plot for CD8+ T cells between VIR and LTNP groups. D. Plot of gene set numbers against FDR value (BDL versus LTNP and VIR versus LTNP in CD8+ T cells, BDL versus LTNP in CD4+ T cells).
Enriched gene sets involved in energy production
| Gene set name | VvsB_CD8 | VvsB_CD4 | VvL_CD8 | VvL_CD4 | BvsL_CD4 |
|---|---|---|---|---|---|
| HSA00190_OXIDATIVE_PHOSPHORYLATION | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| HSA00020_CITRATE_CYCLE | 0.1 | 0.1 | 0.1 | 0.1 | |
| HSA00760_NICOTINATE_AND_NICOTINAMIDE_METABOLISM | 0.05 | 0.05 | 0.1 | 0.05 | |
| TYPE_III_SECRETION_SYSTEM | 0.05 | 0.05 | 0.05 | ||
| PHOTOSYNTHESIS | 0.05 | 0.05 | 0.05 | ||
| ATP_SYNTHESIS | 0.05 | 0.05 | 0.05 | ||
| FLAGELLAR_ASSEMBLY | 0.05 | 0.05 | 0.05 | ||
| MITOCHONDRIAL_FATTY_ACID_BETAOXIDATION | 0.1 | 0.1 | |||
| PYRUVATE_METABOLISM | 0.1 | 0.05 | |||
| HSA00650_BUTANOATE_METABOLISM | 0.05 | 0.1 | 0.05 | 0.05 | |
| HSA00071_FATTY_ACID_METABOLISM | 0.05 | 0.05 | 0.05 | ||
| HSA00670_ONE_CARBON_POOL_BY_FOLATE | 0.1 | 0.1 | 0.1 | ||
| HSA00051_FRUCTOSE_AND_MANNOSE_METABOLISM | 0.1 | 0.1 | 0.1 | ||
| HSA00511_N_GLYCAN_DEGRADATION | 0.05 | 0.05 | 0.1 | ||
| HSA00030_PENTOSE_PHOSPHATE_PATHWAY | 0.1 | 0.1 | |||
| HSA01032_GLYCAN_STRUCTURES_DEGRADATION | 0.05 | 0.05 | |||
| STARCH_AND_SUCROSE_METABOLISM | 0.05 | 0.1 | |||
| HSA00052_GALACTOSE_METABOLISM | 0.1 | 0.1 | |||
| HSA00532_CHONDROITIN_SULFATE_BIOSYNTHESIS | 0.1 | 0.05 | |||
| PROPANOATE_METABOLISM | 0.05 | ||||
| HSA00040_PENTOSE_AND_GLUCURONATE_INTERCONVERSIONS | 0.1 | ||||
| HSA00010_GLYCOLYSIS_AND_GLUCONEOGENESIS | 0.1 | ||||
| GLYCOLYSIS | 0.1 | ||||
| GLUCONEOGENESIS | 0.1 | ||||
| HSA00710_CARBON_FIXATION | 0.1 | ||||
| PROSTAGLANDIN_AND_LEUKOTRIENE_METABOLISM | 0.1 | ||||
| BILE_ACID_BIOSYNTHESIS | 0.05 | ||||
| HSA00531_GLYCOSAMINOGLYCAN_DEGRADATION | 0.1 | ||||
| HSA00565_ETHER_LIPID_METABOLISM | 0.1 | ||||
| FRUCTOSE_AND_MANNOSE_METABOLISM | 0.1 | ||||
| HSA00280_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION | 0.05 | 0.1 | 0.05 | 0.05 | 0.05 |
| LYSINE_DEGRADATION | 0.05 | 0.1 | 0.05 | 0.05 | |
| HSA00230_PURINE_METABOLISM | 0.05 | 0.1 | 0.1 | 0.1 | |
| PHENYLALANINE_METABOLISM | 0.1 | 0.05 | 0.05 | 0.1 | |
| HSA00380_TRYPTOPHAN_METABOLISM | 0.1 | 0.1 | 0.05 | 0.1 | |
| HSA00240_PYRIMIDINE_METABOLISM | 0.05 | 0.1 | 0.05 | ||
| HSA00252_ALANINE_AND_ASPARTATE_METABOLISM | 0.1 | 0.1 | 0.05 | ||
| HSA00410_BETA_ALANINE_METABOLISM | 0.05 | 0.1 | |||
| PORPHYRIN_AND_CHLOROPHYLL_METABOLISM | 0.05 | 0.1 | 0.05 | 0.1 | |
| HSA00330_ARGININE_AND_PROLINE_METABOLISM | 0.1 | ||||
| PROTEASOME | 0.05 | 0.1 | 0.05 | 0.05 | 0.05 |
| PROTEASOMEPATHWAY | 0.1 | 0.1 | 0.1 | ||
| HSA00970_AMINOACYL_TRNA_BIOSYNTHESIS | 0.05 | 0.1 | |||
The presence of curious gene groups photosynthesis, Type III secretion and flagellar assembly is due to the heavy overlapping genes between these pathways and OXPHOS pathway we have found significant in our study. For example, in the group comparison, VIR versus BDL in CD4 T cells, 53 core enrichment genes contributed to the enrichment of OXPHOS pathway and 10 core enrichment genes contributed to the flagellar assembly pathway. All these 10 core genes from flagellar assembly pathway ATP6V1D, ATP6V0D1, ATP6V1A, ATP6V0A1, ATP6V1B2, ATP6AP1, ATP6V1E1, ATP6V1H, ATP6V0B, and ATP6V1F are ALL present in the 53 core genes from OXPHOS pathway. In this overlapping situation, when you do Gene Set Enrichment Analysis (GSEA) using the gene set file (gmt file constructed by gene symbols downloaded from broad institute website), the flagellar pathway will appear together with OXPHOS pathway as the same gene symbol applies to different species and these 2 pathways do have a number of overlapping genes. It is common that at the level of pathway analysis, pathways with certain amount of overlapping genes will always appear together, just like flagellar assembly showed up with the OXPHOS. Our results just reflected the true output from GSEA analysis. We leave them there but at the bottom of the aerobic metabolism category with the consideration that it reflects the same biological theme related to ATP production even though from different species.
VvsB_CD8: Gene sets enriched in the VIR group in the comparison of VIR versus BDL in CD8+ T cells
VvsB_CD4: Gene sets enriched in the VIR group in the comparison of VIR versus BDL in CD4+ T cells
VvL_CD8: Gene sets enriched in the VIR group in the comparison of VIR versus LTNP in CD8+ T cells
VvL_CD4: Gene sets enriched in the VIR group in the comparison of VIR versus LTNP in CD4+ T cells
BvsL_CD4: Gene sets enriched in the BDL group in the comparison of BDL versus LTNP in CD4+ T cells
Gene sets significantly enriched are marked by the number 0.05 or 0.1 in the corresponding paired comparisons 0.05: FDR < or = 0.05; 0.1: FDR < or = 0.1
Gene set information could be searched at the website http://www.broad.mit.edu/gsea/msigdb/search.jsp
Figure 3Enrichment plot and heat map for the gene set of tricarboxylic acid cycle by GSEA. A. Enrichment plot for CD8+ T cells from the VIR group (VIR versus LTNP). Bottom, plot of the ranked list of all genes. Y axis, value of the ranking metric; X axis, the rank for all genes. Genes whose expression levels are most closely associated with the VIR or LTNP group get the highest metric scores with positive or negative sign, and are located at the left or right edge of the list. Middle, the location of genes from the gene set TCA cycle within the ranked list. Top, the running enrichment score for the gene set as the analysis walks along the ranked list. The score at the peak of the plot is the enrichment score (ES) for this gene set and those genes appear before or at the peak are defined as core enrichment genes for this gene set. B. Heat map of the genes within the gene set of TCA cycle corresponding to A. The genes that contribute most to the ES, i.e., genes that appear in the ranked list before or at the peak point of ES, are defined as core enrichment genes and highlighted by the red rectangle. Rows, genes, columns, samples. Range of colors (red to blue) shows the range of expression values (high to low). C. Enrichment plot for CD4+ T cells from the BDL group (BDL versus LTNP). D. Heat map of the genes within the gene set of TCA cycle corresponding to C.
Figure 4Coordinately up-regulated TCA cycle genes in CD8+ T cells from the VIR group (VIR versus LTNP) illustrated in TCA cycle pathway from Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/). The enzymes encoded by coordinately up-regulated TCA cycle genes are highlighted in red and these include ATP citrate lyase (EC:2.3.3.8; gene symbol ACLY), aconitase 1, soluble and aconitase 2, mitochondrial (EC:4.2.1.3; gene symbol ACO1 and ACO2), isocitrate dehydrogenase 2 (NADP+), mitochondrial (EC:1.1.1.42; gene symbol IDH2), isocitrate dehydrogenase 3 (NAD+) gamma (EC:1.1.1.41; gene symbol IDH3G), oxoglutarate (alpha-ketoglutarate) dehydrogenase (EC:1.2.4.2; gene symbol OGDH), succinate-CoA ligase, alpha subunit (EC:6.2.1.4; gene symbol SUCLG1), succinate-CoA ligase, ADP-forming, beta subunit (EC:6.2.1.5; gene symbol SUCLG2), succinate dehydrogenase complex, subunit C (EC:1.3.5.1; gene symbol SDHC), fumarate hydratase (EC:4.2.1.2; gene symbol FH), malate dehydrogenase 1 and 2, (EC:1.1.1.37; gene symbol MDH1 and MDH2), and phosphoenolpyruvate carboxykinase 2 (mitochondrial) (EC:4.1.1.32; gene symbol PCK2). Coordinately up-regulated pathways, which are closely articulated with the TCA cycle, are highlighted by red rectangles. The TCA cycle intermediates linked to other pathways are highlighted by red circles.
Enriched gene sets other than involved in energy production
| Gene set name | VvsB_CD8 | VvsB_CD4 | VvL_CD8 | VvL_CD4 | BvsL_CD4 |
|---|---|---|---|---|---|
| CHEMICALPATHWAY | 0.1 | 0.1 | |||
| APOPTOSIS | 0.1 | 0.1 | |||
| APOPTOSIS_GENMAPP | 0.1 | ||||
| CASPASEPATHWAY | 0.1 | 0.05 | |||
| SA_CASPASE_CASCADE | 0.05 | ||||
| DNA_REPLICATION_REACTOME | 0.05 | 0.05 | 0.1 | ||
| G1_TO_S_CELL_CYCLE_REACTOME | 0.05 | ||||
| HSA04110_CELL_CYCLE | 0.05 | ||||
| CELL_CYCLE_KEGG | 0.05 | ||||
| CELLCYCLEPATHWAY | 0.05 | ||||
| G2PATHWAY | 0.1 | ||||
| G1PATHWAY | 0.1 | ||||
| P53PATHWAY | 0.1 | ||||
| MPRPATHWAY | 0.1 | ||||
| ST_GA12_PATHWAY | 0.05 | ||||
| HSA04612_ANTIGEN_PROCESSING_AND_PRESENTATION | 0.05 | 0.05 | 0.05 | ||
| HSA04650_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY | 0.05 | 0.05 | 0.05 | ||
| COMPPATHWAY | 0.05 | 0.05 | 0.05 | ||
| HSA04610_Complement_and_coagulation-cascades | 0.05 | 0.05 | |||
| INTRINSICPATHWAY | 0.1 | 0.1 | |||
| HSA04620_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY | 0.05 | 0.1 | |||
| TOLLPATHWAY | 0.05 | ||||
| HSA04662_B_CELL_RECEPTOR_SIGNALING_PATHWAY | 0.1 | ||||
| SA_B_CELL_RECEPTOR_COMPLEXES | 0.1 | ||||
| RHOPATHWAY | 0.05 | 0.05 | 0.05 | 0.05 | |
| NDKDYNAMINPATHWAY | 0.1 | ||||
| SIG_REGULATION_OF_THE_ACTIN_CYTOSKELETON_BY_RHO_GTPASES | 0.1 | ||||
| INTEGRIN_MEDIATED_CELL_ADHESION_KEGG | 0.1 | ||||
| IL12PATHWAY | 0.1 | ||||
| NO2IL12PATHWAY | 0.1 | ||||
| TIDPATHWAY | 0.1 | ||||
| IL6PATHWAY | 0.1 | ||||
| IL3PATHWAY | 0.1 | ||||
| SPPAPATHWAY | 0.1 | ||||
| HSA05120_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION | 0.05 | ||||
| HSA05131_PATHOGENIC_ESCHERICHIA_COLI_INFECTION_EPEC | 0.1 | ||||
| HSA05130_PATHOGENIC_ESCHERICHIA_COLI_INFECTION_EHEC | 0.1 | ||||
| HSA04320_DORSO_VENTRAL_AXIS_FORMATION | 0.1 | ||||
| HSA05219_BLADDER_CANCER | 0.1 | ||||
VvsB_CD8: Gene sets enriched in the VIR group in the comparison of VIR versus BDL in CD8+ T cells
VvsB_CD4: Gene sets enriched in the VIR group in the comparison of VIR versus BDL in CD4+ T cells
VvL_CD8: Gene sets enriched in the VIR group in the comparison of VIR versus LTNP in CD8+ T cells
VvL_CD4: Gene sets enriched in the VIR group in the comparison of VIR versus LTNP in CD4+ T cells
BvsL_CD4: Gene sets enriched in the BDL group in the comparison of BDL versus LTNP in CD4+ T cells
Gene sets significantly enriched are marked by the number 0.05 or 0.1 in the corresponding paired comparisons 0.05: FDR < or = 0.05; 0.1: FDR < or = 0.1
Gene set information could be searched at the website http://www.broad.mit.edu/gsea/msigdb/search.jsp
Figure 5Coordinately up-regulated cell cycle genes in CD8+ T cells from the VIR group (VIR versus BDL) illustrated in cell cycle pathway from Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/). The proteins encoded by coordinately up-regulated cell cycle genes are highlighted in red.
Enriched pathways in CD4+ T cells from the LTNP group (BDL versus LTNP)
| Gene set name | Gene set size | NES | NOM p-val | FDR |
|---|---|---|---|---|
| NTHIPATHWAY | 22 | -2.05 | 0.000 | 0.008 |
| ST_JNK_MAPK_PATHWAY | 40 | -1.88 | 0.002 | 0.038 |
| ST_GRANULE_CELL_SURVIVAL_PATHWAY | 26 | -1.77 | 0.002 | 0.049 |
| IGF1PATHWAY | 20 | -1.77 | 0.002 | 0.049 |
| INSULINPATHWAY | 21 | -1.79 | 0.004 | 0.050 |
| NGFPATHWAY | 19 | -1.81 | 0.002 | 0.053 |
| CARDIACEGFPATHWAY | 17 | -1.75 | 0.000 | 0.056 |
| 41BBPATHWAY | 18 | -1.74 | 0.014 | 0.058 |
| CDMACPATHWAY | 16 | -1.71 | 0.010 | 0.073 |
| HSA04012_ERBB_SIGNALING_PATHWAY | 87 | -1.70 | 0.008 | 0.074 |
| SA_TRKA_RECEPTOR | 16 | -1.70 | 0.012 | 0.075 |
| HSA04010_MAPK_SIGNALING_PATHWAY | 256 | -1.64 | 0.000 | 0.087 |
| PDGFPATHWAY | 27 | -1.66 | 0.012 | 0.088 |
| TPOPATHWAY | 23 | -1.66 | 0.012 | 0.089 |
| EGFPATHWAY | 27 | -1.66 | 0.018 | 0.091 |
| INFLAMPATHWAY | 29 | -1.99 | 0.000 | 0.017 |
| CYTOKINEPATHWAY | 20 | -1.95 | 0.000 | 0.023 |
| CCR5PATHWAY | 18 | -1.78 | 0.006 | 0.049 |
| TCRPATHWAY | 43 | -1.80 | 0.006 | 0.052 |
| IL6PATHWAY | 21 | -1.79 | 0.002 | 0.054 |
| IL1RPATHWAY | 32 | -1.82 | 0.000 | 0.055 |
| IL12PATHWAY | 20 | -1.68 | 0.018 | 0.083 |
| TOLLPATHWAY | 34 | -1.66 | 0.012 | 0.086 |
| HSA04060_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION | 253 | -1.65 | 0.000 | 0.087 |
| HSA04660_T_CELL_RECEPTOR_SIGNALING_PATHWAY | 93 | -1.65 | 0.006 | 0.089 |
| CALCINEURIN_NF_AT_SIGNALING | 92 | -1.92 | 0.000 | 0.030 |
| HYPERTROPHY_MODEL | 17 | -1.91 | 0.000 | 0.025 |
| ATMPATHWAY | 19 | -1.86 | 0.000 | 0.043 |
| HSA05210_COLORECTAL_CANCER | 85 | -1.78 | 0.000 | 0.049 |
| SMOOTH_MUSCLE_CONTRACTION | 140 | -1.83 | 0.000 | 0.051 |
| CIRCADIAN_EXERCISE | 40 | -1.79 | 0.000 | 0.051 |
| GPCRPATHWAY | 35 | -1.76 | 0.006 | 0.054 |
| ST_DIFFERENTIATION_PATHWAY_IN_PC12_CELLS | 42 | -1.73 | 0.002 | 0.064 |
| P53HYPOXIAPATHWAY | 19 | -1.68 | 0.022 | 0.082 |
Gene set size: number of genes in a particular gene set; NES: normalized enrichment score;
NOM p-val: nominal p value; FDR: false discovery rate
Gene set information could be searched at the website http://www.broad.mit.edu/gsea/msigdb/search.jsp
Figure 6Branches of MAPK pathway significantly enriched in CD4+ T cells from the LTNP group (BDL versus LTNP). Listed genes except for p38 and ERK1/2 are the core enrichment genes derived from MAPK associated pathways and directly involved in the MAPK cascade. The possible roles of each branch of MAPK pathway contributing to the LTNP status are also shown.
Figure 7Schematic overview of the network of enriched pathways related to HIV disease progression. HIV accessory proteins and side effects of therapy could lead to the impaired activity of electron transport chain complex I, which results in mitochondrial dysfunction. As a compensatory effect, OXPHOS pathway (electron transport chain and ATP synthase) is up-regulated as indicated by the red arrow. Along with the OXPHOS pathway, the TCA cycle supplying NADH to OXPHOS, and a wide range of metabolic pathways (carbohydrate, fatty acid, protein, and amino acid metabolism pathways) furnishing substrates to the TCA cycle are coordinately up-regulated. In addition, mitochondrial dysfunction leads to cell apoptosis mediated by the activation of mitochondrial membrane pore-forming proteins, such as BAX and BAD. Pores generated in the mitochondrial membranes allow the release of the pro-apoptotic proteins cytochrome c, which binds to APAF and hence activates CASP9 leading to the caspase cascade resulting in apoptosis. G2 arrest and DNA damage signaling could also activate BAX leading to mitochondria-mediated apoptosis. On the other hand, AKT could prevent apoptosis by either inhibiting BAD or CASP9 activation or preventing FOXO factors from relocating to the nucleus.